Refill persistence with chronic medication assessed from a pharmacy database was influenced by method of calculation

Journal of Clinical Epidemiology

Volumn 59, Issue 1, 2006, Pages 11-17

  Van Wijk, Boris L G ^a   Klungel, Olaf H ^a   Heerdink, Eibert R ^a   De Boer, Anthonius ^a  

^a UTRECHT UNIVERSITY   (Netherlands)

Author keywords

Antihypertensives; Compliance; Hypertension; Persistence; Pharmacy records; Refill persistence

Indexed keywords

ANGIOTENSIN II ANTAGONIST; ANTIASTHMATIC AGENT; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT;

ADULT; AGED; ARTICLE; CALCULATION; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; DATA BASE; DEMOGRAPHY; DRUG USE; FEMALE; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; PHARMACY; PRESCRIPTION; PRIORITY JOURNAL;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; CHILD; CHILD, PRESCHOOL; CHRONIC DISEASE; COHORT STUDIES; DATABASES; FEMALE; HOSPITALIZATION; HUMANS; HYPERTENSION; INFANT; MALE; MIDDLE AGED; PATIENT COMPLIANCE; RECEPTORS, ANGIOTENSIN; SEX FACTORS; TIME FACTORS;

EID: 29144477779     PISSN: 08954356     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jclinepi.2005.05.005     Document Type: Article

References (25)

1. R. Herings Chronic pharmacotherapy forever 2002 PHARMO institute Utrecht
2. J. Urquhart Some economic consequences of noncompliance Curr Hypertens Rep 3 6 2001 473 480
3. L.A. Garcia Rodriguez, and S. Perez Gutthann Use of the UK General Practice Research Database for pharmacoepidemiology Br J Clin Pharmacol 45 5 1998 419 425
4. R. Herings PHARMO: a record linkage system for postmarketing surveillance of prescription drugs in the Netherlands 1993 Utrecht University Utrecht
5. E. Malcolm, W. Downey, L. Stand, M. McNutt, and R. West Saskatchewan Health's linkable databases and pharmacoepidemiology Post Marketing Surveill 6 1993 175 264
6. B.L. Strom, J.L. Carson, M.L. Morse, and A.A. LeRoy The computerized online Medicaid pharmaceutical analysis and surveillance system: a new resource for postmarketing drug surveillance Clin Pharmacol Ther 38 1985 359 364
7. S. Benson, K. Vance-Bryan, and J. Raddatz Time to patient discontinuation of antihypertensive drugs in different classes Am J Health Syst Pharm 57 1 2000 51 54
8. B.S. Bloom Continuation of initial antihypertensive medication after 1 year of therapy Clin Ther 20 4 1998 671 681
9. V.S. Catalan, and J. LeLorier Predictors of long-term persistence on statins in a subsidized clinical population Value Health 3 2000 417 426
10. V.S. Catalan, J.A. Couture, and J. LeLorier Predictors of persistence of use of the novel antidiabetic agent acarbose Arch Intern Med 161 8 2001 1106 1112
11. C.M. Dezii A retrospective study of persistence with single-pill combination therapy vs. concurrent two-pill therapy in patients with hypertension Manage Care 10 2 Suppl 2001 6 10
12. J. Hasford, A. Mimran, and W.R. Simons A population-based European cohort study of persistence in newly diagnosed hypertensive patients J Hum Hypertens 16 8 2002 569 575
13. J.K. Jones, L. Gorkin, J.F. Lian, J.A. Staffa, and A.P. Fletcher Discontinuation of and changes in treatment after start of new courses of antihypertensive drugs: a study of a United Kingdom population BMJ 311 7000 1995 293 295
14. M.A. Marentette, W.C. Gerth, D.K. Billings, and K.B. Zarnke Antihypertensive persistence and drug class Can J Cardiol 18 6 2002 649 656
15. O. Sheehy, and J. LeLorier Patterns of amlodipine and felodipine use in an elderly Quebec population Can J Cardiol 16 9 2000 1109 1117
16. Guidelines for ATC Classification and DDD assignment, WHO Collaborating Centre for Drug Statistics Methodology - Nordic Council on Medicines, Oslo 1999 World Health Organization Geneva
17. M. Moser World Health Organization-International Society of Hypertension guidelines for the management of hypertension - do these differ from the U.S. recommendations? Which guidelines should the practicing physician follow? J Clin Hypertens (Greenwich) 1 1 1999 48 54
18. WHO Guidelines for ATC Classification and DDD assignment, WHO Collaborating Centre for Drug Statistics Methodology - Nordic Council on Medicines, Oslo 1999 WHO Geneva
19. H.S. Lau, A. de Boer, K.S. Beuning, and A. Porsius Validation of pharmacy records in drug exposure assessment J Clin Epidemiol 50 5 1997 619 625
20. D.G. Altman Comparing group: categorical data D.G. Altman Practical statistic for medical research 1995 Chapman & Hall London 229 276
21. L.D. Esposti, M. Di Martino, S. Saragoni, A. Sgreccia, A. Capone, and S. Buda Pharmacoeconomics of antihypertensive drug treatment: an analysis of how long patients remain on various antihypertensive therapies J Clin Hypertens (Greenwich) 6 2 2004 76 84
22. J. Wogen, C.A. Kreilick, R.C. Livornese, K. Yokoyama, and F. Frech Patient adherence with amlodipine, lisinopril, or valsartan therapy in a usualcare setting J Manag Care Pharm 9 5 2003 424 429
23. J.F. Steiner, and A.V. Prochazka The assessment of refill compliance using pharmacy records: methods, validity, and applications J Clin Epidemiol 50 1 1997 105 116
24. P.R. Conlin, W.C. Gerth, J. Fox, J.B. Roehm, and S.J. Boccuzzi Four-year persistence patterns among patients initiating therapy with the angiotensin II receptor antagonist losartan versus other artihypertensive drug classes Clin Ther 23 12 2001 1999 2010
25. E. Degli Esposti, A. Sturani, M. Di Martino, P. Falasca, M.V. Novi, and G. Baio Long-term persistence with antihypertensive drugs in new patients J Hum Hypertens 16 6 2002 439 444